The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
The amino terminus of tau inhibits kinesin‐dependent axonal transport: Implications for filament toxicity
Open accessAbstract
The neuropathology of Alzheimer's disease (AD) and other tauopathies is characterized by filamentous deposits of the microtubule‐associated protein tau, but the relationship between tau polymerization and neurotoxicity is unknown. Here, we examined effects of filamentous tau on fast axonal transport (FAT) using isolated squid axoplasm. Monomeric and filamentous forms of recombinant human tau were perfused in axoplasm, and their effects on kinesin‐ and dynein‐dependent FAT rates were evaluated by video microscopy. Although perfusion of monomeric tau at physiological concentrations showed no effect, tau filaments at the same concentrations selectively inhibited anterograde (kinesin‐dependent) FAT, triggering the release of conventional kinesin from axoplasmic vesicles. Pharmacological experiments indicated that the effect of tau filaments on FAT is mediated by protein phosphatase 1 (PP1) and glycogen synthase kinase‐3 (GSK‐3) activities. Moreover, deletion analysis suggested that these effects depend on a conserved 18‐amino‐acid sequence at the amino terminus of tau. Interestingly, monomeric tau isoforms lacking the C‐terminal half of the molecule (including the microtubule binding region) recapitulated the effects of full‐length filamentous tau. Our results suggest that pathological tau aggregation contributes to neurodegeneration by altering a regulatory pathway for FAT. © 2008 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model
Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S.-M., Iwata, N., Saido, T. C., Maeda, J., Suhara, T., Trojanowski, J. Q., & Lee, V. M.-Y. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.010 · Cited by 2,208
Domains of tau Protein and Interactions with Microtubules
Gustke, N., Trinczek, B., Biernat, J., Mandelkow, E.-M., & Mandelkow, E. (1994) · Biochemistry · doi:10.1021/bi00198a017 · Cited by 655
The microtubule binding domain of tau protein
Lee, G., Neve, R. L., & Kosik, K. S. (1989) · Neuron · doi:10.1016/0896-6273(89)90050-0 · Cited by 500 · cited 2×
“Tau6P and Tau6D terminate prior to the MTBR region, and so are not expected to interact with microtubules (Lee et al. 1989) or form filaments (Abraha et al.”
BackgroundMultiple-motor based transport and its regulation by Tau
Vershinin, M., Carter, B. C., Razafsky, D. S., King, S. J., & Gross, S. P. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607919104 · Cited by 457
Global Hairpin Folding of Tau in Solution
Jeganathan, S., von Bergen, M., Brutlach, H., Steinhoff, H.-J., & Mandelkow, E. (2006) · Biochemistry · doi:10.1021/bi0521543 · Cited by 432
Single-molecule investigation of the interference between kinesin, tau and MAP2c
Seitz, A., Kojima, H., Oiwa, K., Mandelkow, E.-M., Song, Y.-H., & Mandelkow, E. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf503 · Cited by 257 · cited 2×
“Although reports have been published arguing both for (Ebneth et al. 1998; Seitz et al. 2002; Vershinin et al. 2007), and against (Morfini et al. 2007a) the idea that high levels of soluble tau can reduce anterograde FAT by interfering with the attachment of the molecular motor kinesin, there is no…”
BackgroundNMDA receptor mediates tau-induced neurotoxicity by calpain and ERK/MAPK activation
Amadoro, G., Ciotti, M. T., Costanzi, M., Cestari, V., Calissano, P., & Canu, N. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511065103 · Cited by 243
Early N-Terminal Changes and Caspase-6 Cleavage of Tau in Alzheimer's Disease
Horowitz, P. M., Patterson, K. R., Guillozet-Bongaarts, A. L., Reynolds, M. R., Carroll, C. A., Weintraub, S. T., Bennett, D. A., Cryns, V. L., Berry, R. W., & Binder, L. I. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.1988-04.2004 · Cited by 215
Self-citationGhoshal, N. (2002) · Experimental Neurology · doi:10.1006/exnr.2002.8014 · Cited by 192
Coffey, E. T., Smiciene, G., Hongisto, V., Cao, J., Brecht, S., Herdegen, T., & Courtney, M. J. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-11-04335.2002 · Cited by 184 · cited 2×
“2006), a pharmacological inhibitor that acts on JNK2/3 and other members of the stress-activated protein kinase (SAPK)/JNK family (Coffey et al. 2002; Morfini et al. 2006).”
Background
Cited by
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
The Intersection of Amyloid Beta and Tau at Synapses in Alzheimer’s Disease
Spires-Jones, T. L., & Hyman, B. T. (2014) · Neuron · doi:10.1016/j.neuron.2014.05.004 · Cited by 1,201
Antonarakis, S. E., Skotko, B. G., Rafii, M. S., Strydom, A., Pape, S. E., Bianchi, D. W., Sherman, S. L., & Reeves, R. H. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0143-7 · Cited by 964
Axonal transport deficits and neurodegenerative diseases
Millecamps, S., & Julien, J.-P. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3380 · Cited by 755
Post-translational modifications of tau protein: Implications for Alzheimer's disease
Martin, L., Latypova, X., & Terro, F. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2010.12.023 · Cited by 641
Tau protein kinases: Involvement in Alzheimer's disease
Martin, L., Latypova, X., Wilson, C. M., Magnaudeix, A., Perrin, M.-L., Yardin, C., & Terro, F. (2013) · Ageing Research Reviews · doi:10.1016/j.arr.2012.06.003 · Cited by 631
Arendt, T., Stieler, J. T., & Holzer, M. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.08.018 · Cited by 609
Traffic control: regulation of kinesin motors
Verhey, K. J., & Hammond, J. W. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2782 · Cited by 546
The role of tau in neurodegeneration
Gendron, T. F., & Petrucelli, L. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-13 · Cited by 478
Structure and Pathology of Tau Protein in Alzheimer Disease
Kolarova, M., García-Sierra, F., Bartos, A., Ricny, J., & Ripova, D. (2012) · International Journal of Alzheimer's Disease · doi:10.1155/2012/731526 · Cited by 468
Axonal Transport Defects in Neurodegenerative Diseases
Morfini, G. A., Burns, M., Binder, L. I., Kanaan, N. M., LaPointe, N., Bosco, D. A., Brown, R. H., Brown, H., Tiwari, A., Hayward, L., et al. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3463-09.2009 · Cited by 464
Self-citationTau Protein Modifications and Interactions: Their Role in Function and Dysfunction
Mietelska-Porowska, A., Wasik, U., Goras, M., Filipek, A., & Niewiadomska, G. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15034671 · Cited by 404
Characterization of Prefibrillar Tau Oligomers in Vitro and in Alzheimer Disease
Patterson, K. R., Remmers, C., Fu, Y., Brooker, S., Kanaan, N. M., Vana, L., Ward, S., Reyes, J. F., Philibert, K., Glucksman, M. J., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.237974 · Cited by 357
Self-citationMoloney, C. M., Lowe, V. J., & Murray, M. E. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12321 · Cited by 330
Tau Oligomers: Cytotoxicity, Propagation, and Mitochondrial Damage
Shafiei, S. S., Guerrero-Muñoz, M. J., & Castillo-Carranza, D. L. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00083 · Cited by 314
GSK-3 and tau: a key duet in Alzheimer’s disease
Sayas, C. L., & Ávila, J. (2021) · Cells · doi:10.3390/cells10040721 · Cited by 314
“Tau hyperphosphorylation induces MT disassembly, which impairs motor protein and cargo binding [115].”
BackgroundStability properties of neuronal microtubules
Baas, P. W., Rao, A. N., Matamoros, A. J., & Leo, L. (2016) · Cytoskeleton · doi:10.1002/cm.21286 · Cited by 301
Kopeikina, K. J., Carlson, G. A., Pitstick, R., Ludvigson, A. E., Peters, A., Luebke, J. I., Koffie, R. M., Frosch, M. P., Hyman, B. T., & Spires-Jones, T. L. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.07.004 · Cited by 276
Pathogenic huntingtin inhibits fast axonal transport by activating JNK3 and phosphorylating kinesin
Morfini, G. A., You, Y.-M., Pollema, S. L., Kaminska, A., Liu, K., Yoshioka, K., Björkblom, B., Coffey, E. T., Bagnato, C., Han, D., et al. (2009) · Nature Neuroscience · doi:10.1038/nn.2346 · Cited by 275
Self-citationKanaan, N. M., Morfini, G. A., LaPointe, N. E., Pigino, G. F., Patterson, K. R., Song, Y., Andreadis, A., Fu, Y., Brady, S. T., & Binder, L. I. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.0560-11.2011 · Cited by 272
Self-citationExtracellular Tau Oligomers Produce An Immediate Impairment of LTP and Memory
Fá, M., Puzzo, D., Piacentini, R., Staniszewski, A., Zhang, H., Baltrons, M. A., Li Puma, D. D., Chatterjee, I., Li, J., Saeed, F., et al. (2016) · Scientific Reports · doi:10.1038/srep19393 · Cited by 272
Mitochondrial Aspects of Synaptic Dysfunction in Alzheimer’s Disease
Cai, Q., & Tammineni, P. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160726 · Cited by 272
HDAC6 Regulates Mitochondrial Transport in Hippocampal Neurons
Chen, S., Owens, G. C., Makarenkova, H., & Edelman, D. B. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010848 · Cited by 270
Soluble forms of tau are toxic in Alzheimer's disease
Kopeikina, K., Hyman, B., & Spires-Jones, T. (2012) · Translational Neuroscience · doi:10.2478/s13380-012-0032-y · Cited by 232
“Aggregates of misfolded tau (NFT and neuropil threads) have been argued to interfere with transport by serving as a space-occupying lesion, thereby inhibiting kinesin binding and movement [85, 86].”
BackgroundKinesin Assembly and Movement in Cells
Verhey, K. J., Kaul, N., & Soppina, V. (2011) · Annual Review of Biophysics · doi:10.1146/annurev-biophys-042910-155310 · Cited by 231
Ochalek, A., Mihalik, B., Avci, H. X., Chandrasekaran, A., Téglási, A., Bock, I., Giudice, M. L., Táncos, Z., Molnár, K., László, L., et al. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0317-z · Cited by 225
Are tau aggregates toxic or protective in tauopathies?
Cowan, C. M., & Mudher, A. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00114 · Cited by 215
Tau reduction prevents Aβ-induced axonal transport deficits by blocking activation of GSK3β
Vossel, K. A., Xu, J. C., Fomenko, V., Miyamoto, T., Suberbielle, E., Knox, J. A., Ho, K., Kim, D. H., Yu, G.-Q., & Mucke, L. (2015) · Journal of Cell Biology · doi:10.1083/jcb.201407065 · Cited by 167
Vana, L., Kanaan, N. M., Ugwu, I. C., Wuu, J., Mufson, E. J., & Binder, L. I. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.07.044 · Cited by 138
Self-citationPhosphorylation in the amino terminus of tau prevents inhibition of anterograde axonal transport
Kanaan, N. M., Morfini, G., Pigino, G., LaPointe, N. E., Andreadis, A., Song, Y., Leitman, E., Binder, L. I., & Brady, S. T. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.06.006 · Cited by 134
Self-citationThe Role of Tau Oligomers in the Onset of Alzheimer's Disease Neuropathology
Cárdenas-Aguayo, M. D. C., Gómez-Virgilio, L., DeRosa, S., & Meraz-Ríos, M. A. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500148z · Cited by 120
Ambegaokar, S. S., & Jackson, G. R. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr432 · Cited by 113
Tau biology, tauopathy, traumatic brain injury, and diagnostic challenges
Castellani, R. J., & Perry, G. (2019) · Journal of Alzheimer’s Disease · doi:10.3233/jad-180721 · Cited by 110
Axonal degeneration in tauopathies: disease relevance and underlying mechanisms
Kneynsberg, A., Combs, B., Christensen, K., Morfini, G., & Kanaan, N. M. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00572 · Cited by 102
“, 1999), regulation of AT (LaPointe et al., 2009; Kanaan et al., 2011), nuclear and nucleolar functions (Papasozomenos and Binder, 1987; Loomis et al.”
BackgroundSelf-citationThe toxicity of tau in Alzheimer disease: turnover, targets and potential therapeutics
Pritchard, S. M., Dolan, P. J., Vitkus, A., & Johnson, G. V. W. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01273.x · Cited by 89
“For this reason, tauinduced mitochondrial mislocalization may be a key component in neurodegenerative processes [108, 112].”
BackgroundPhosphorylation of Human Tau Protein by Microtubule Affinity-Regulating Kinase 2
Schwalbe, M., Biernat, J., Bibow, S., Ozenne, V., Jensen, M. R., Kadavath, H., Blackledge, M., Mandelkow, E., & Zweckstetter, M. (2013) · Biochemistry · doi:10.1021/bi401266n · Cited by 78
Phosphoregulation of Tau modulates inhibition of kinesin-1 motility
Stern, J. L., Lessard, D. V., Hoeprich, G. J., Morfini, G. A., & Berger, C. L. (2017) · Molecular Biology of the Cell · doi:10.1091/mbc.e16-10-0728 · Cited by 69
Self-citationThe Pathophysiology of Axonal Transport in Alzheimer's Disease
Vicario-Orri, E., Opazo, C. M., & Muñoz, F. J. (2014) · Journal of Alzheimer’s Disease · doi:10.3233/jad-141080 · Cited by 41
Tau differentially regulates the transport of early endosomes and lysosomes
Balabanian, L., Lessard, D. V., Swaminathan, K., Yaninska, P., Sébastien, M., Wang, S., Stevens, P. W., Wiseman, P. W., Berger, C. L., & Hendricks, A. G. (2022) · Molecular Biology of the Cell · doi:10.1091/mbc.e22-01-0018 · Cited by 26
Maeda, S., & Takashima, A. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-32-9358-8_27 · Cited by 22
Metadata
- Authors
- LaPointe, N. E., Morfini, G., Pigino, G., Gaisina, I. N., Kozikowski, A. P., Binder, L. I., & Brady, S. T.
- Venue
- Journal of Neuroscience Research
- Publisher
- Wiley
- Published
- 2008-09-16
- Volume
- 87
- Issue
- 2
- Pages
- 440-451
- ISSN
- 0360-4012 (ISSN-L)
- 1097-4547
- OpenAlex
- W1969076369
- Cited by
- 240
- References
- 11
- FWCI
- 8.85
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.